Quick Answer
Viking Therapeutics, Inc. reported Research And Development Expense of $344.96 million for the year ending 2025.
- Viking Therapeutics, Inc. showed an increase of +239.4% in Research And Development Expense from 2024 to 2025.
- This data is from Viking Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Viking Therapeutics, Inc.'s Research And Development Expense has grown by 1,452.2%.
- Historical annual values: Fiscal year 2025: $344.96 million | Fiscal year 2024: $101.64 million | Fiscal year 2023: $63.81 million | Fiscal year 2022: $54.23 million | Fiscal year 2021: $44.98 million | Fiscal year 2020: $31.93 million | Fiscal year 2019: $23.56 million | Fiscal year 2018: $19.04 million | Fiscal year 2017: $13.74 million | Fiscal year 2016: $9.00 million | Fiscal year 2015: $6.97 million | Fiscal year 2014: $22.22 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: